biopharma

Pick anything below and it plays in the bar at the foot of the window — and keeps playing while you go on browsing the directory.

1. 1▶Bonus Episode: Inside Endocyclic’s Precision Peptide Strategy For Endometriosis Diagnosis And TreatmentCiteline Podcasts32:49
   +Listen later
2. 2▶Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDABioCentury This Week25:28
   +Listen later
3. 3▶Strategic Intent: The Rise Of Mid-Cap DealmakersCiteline Podcasts16:25
   +Listen later
4. 4▶Building The GLP-1 Companion Category, With Beverley Law And Martina GrippCiteline Podcasts47:40
   +Listen later
5. 5▶Drug Fix: Understanding The PDUFA VIII Revenue Cut And GDUFA IV Name ChangeCiteline Podcasts28:42
   +Listen later
6. 6▶The State of Play in Biotech and the Decisions Shaping the IndustryCiteline Podcasts1:00:58
   +Listen later
7. 7▶Strategic Intent: First-in-class, two markets: Annexon’s GBS and GA StrategiesCiteline Podcasts33:35
   +Listen later
8. 8▶Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOsBioCentury This Week31:43
   +Listen later
9. 9▶Drug Fix: Regulatory Nationalism And US FDA’s IND ReformsCiteline Podcasts24:29
   +Listen later
10. 10▶Proof of Concept - AI in Drug DiscoveryCiteline Podcasts46:43
    +Listen later
11. 11▶Digital Health Roundup: CE Mark For Vision-Restoring Implant, AI Chatbot Rules, MS DealCiteline Podcasts11:52
    +Listen later
12. 12▶Podcast: China's Evolving Role in Global Clinical DevelopmentCiteline Podcasts17:39
    +Listen later
13. 13▶Off-Patent, On Record: View Through The Journalist's Lens With Generics Bulletin's Dave WallaceCiteline Podcasts24:16
    +Listen later
14. 14▶Ep. 380 - AZ-BMS rumors, Replimune, psychedelicsBioCentury This Week32:25
    +Listen later
15. 15▶Lance Baldo: CEO of Beacon TherapeuticsBioBoss26:10Notes
    +Listen later
16. 16▶Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecardBioCentury This Week34:09
    +Listen later
17. 17▶Summer Rhythm: Getting Ready for FallConnecting the Dots5:51Notes
    +Listen later
18. 18▶Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen dataBioCentury This Week42:07
    +Listen later
19. 19▶Ep. 377 - Trends in life sciences talent with CBRE's Ian AndersonBioCentury This Week29:16
    +Listen later
20. 20▶Ep. 376 - M&A momentum: 3Q public markets previewBioCentury This Week33:01
    +Listen later
21. 21▶Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotechBioCentury This Week33:44
    +Listen later
22. 22▶Ep. 374 - Parkinson's deep dive & FDA trial reformsBioCentury This Week34:14
    +Listen later
23. 23▶Shaun Bagai: CEO of RenovoRXBioBoss33:52Notes
    +Listen later
24. 24▶Ep. 373 - AbbVie M&A, FDA reversals, a CAR T firstBioCentury This Week30:10
    +Listen later
25. 25▶The Identity Crisis at the Heart of Medical AffairsConnecting the Dots8:32Notes
    +Listen later
26. 26▶The Human Role in Launch ReadinessConnecting the Dots8:03Notes
    +Listen later
27. 27▶Hyung Heon Kim: CEO of MetaViaBioBoss32:28Notes
    +Listen later
28. 28▶Process Unleashes InnovationConnecting the Dots8:04Notes
    +Listen later
29. 29▶David Southwell: CEO of Volastra TherapeuticsBioBoss31:26Notes
    +Listen later
30. 30▶Medical Affairs Today – A discussion with two expertsConnecting the Dots27:39Notes
    +Listen later
31. 31▶The Right Forum, at the Right TimeConnecting the Dots6:42Notes
    +Listen later
32. 32▶Stacy Lindborg: CEO of ImunonBioBoss33:40Notes
    +Listen later
33. 33▶Welcome to Season 8 of BioBossBioBoss1:22Notes
    +Listen later
34. 34▶100 Dots Connected: Reflecting on Eight Years of ConversationsConnecting the Dots9:47Notes
    +Listen later
35. 35▶Michael Cloonan: CEO of Sionna TherapeuticsBioBoss44:22Notes
    +Listen later
36. 36▶Erik van den Berg: CEO of Memo TherapeuticsBioBoss30:59Notes
    +Listen later
37. 37▶Bruce Leuchter: CEO of Neurvati NeurosciencesBioBoss46:15Notes
    +Listen later
38. 38▶Connecting in a Volatile Job MarketConnecting the Dots9:55Notes
    +Listen later
39. 39▶Todd Harris: CEO of Tyra BiosciencesBioBoss29:13Notes
    +Listen later
40. 40▶Building Credibility as a New LeaderConnecting the Dots6:24Notes
    +Listen later
41. 41▶BIO and Boston: The Global Stage and HLYBConnecting the Dots6:35Notes
    +Listen later